Filing excerpt
...representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.
sec.gov/Archives/edgar/data/1551152/000155115226000021/abbv-20260706.htmRead the full source
AbbVie8-K: Margin pressure
AbbVie's Q2 2026 earnings per share to take a $0.17 hit from R&D acquisition costs
What happened
A $291M expense for acquired R&D will reduce Q2 earnings per share by $0.17, putting pressure on short-term profitability. This may increase focus on operational efficiency and cost management in other departments to meet overall financial targets.
Source
Other signals in this filing (2)
- Capex increaseAbbVie invests $291M in acquired R&D and milestones in Q2 2026Capex increase
- Acquisition announcedAbbVie signals recent acquisition or licensing deal with $291M R&D expense in Q2 2026Acquisition announced
Extracted by Autobound
From the Signal API record- Signal
- 8-K: Margin pressure
What this signalsFilings often name leadership changes, deals and spending plans.
- Form
- 8-K
- Fiscal year end
- 07/06
- Filed
- Jul 6, 2026
More from AbbVie
- PartnershipAbbVie Teams Up With Valkai to Use AI in Clinical DevelopmentPartnership
- IntegrationValkai partners with AbbVie to apply advanced AI in targeted areas of clinical developmentIntegration
- PatentsAbbVie Inc.'s patent output is steady: 3 grants in the past year, 0 in the past 30 days.Patents
- LaunchU.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's DiseaseLaunch
- RedditCommenters describe AbbVie as a challenging employer for Clinical Research Associates, citing a "ridiculous" work-life balance and a "toxic" environment with frequent, disruptive rollouts of new...Reddit
- InvestmentDrug developer ADARx seeks $1.74 billion valuation in US IPOInvestment
More 8-K signals at other companies
- SEC 8-K4D Molecular Therapeutics, Inc.4D Molecular Therapeutics initiates Phase 3 trial directly challenging competitor drug aflibercept.SEC 8-K
- SEC 8-KAdeia Inc.Adeia Inc. appoints new CEO Dipti Vachani, effective October 12, 2026, replacing outgoing CEO Paul E. Davis.SEC 8-K
- SEC 8-KAdicet Bio, Inc.Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.SEC 8-K
The full record
From the Signal API recordDetails
- CIK
- 1551152
- Accession number
- 0001551152-26-000021
- Metric named
- The key metric is a $0.17 impact on earnings per share.
- Timeframe
- Current quarter
- Filing year
- 2026
- Why it matters
- Efficiency tools needed
- Signal category
- Financial
Extraction
- Confidence
- High
- Relevance
- 80%
- Sentiment
- Negative
- Detected
- Jul 7, 2026
- signal_type
sec-8k- signal_subtype
marginPressure
Use this data
Get every 8-K signal for AbbVie and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
Send it to your own tools
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/54131994-c3c2-4e71-9101-434e802cb548 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "54131994-c3c2-4e71-9101-434e802cb548",
"signal_type": "sec-8k",
"signal_subtype": "marginPressure",
"detected_at": "2026-07-07T07:08:16.906+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "A $291M expense for acquired R&D will reduce Q2 earnings per share by $0.17, putting pressure on short-term profitability. This may increase focus on operational efficiency and cost management in other departments to meet overall financial targets.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "The key metric is a $0.17 impact on earnings per share."
},
"summary": "AbbVie's Q2 2026 earnings per share to take a $0.17 hit from R&D acquisition costs",
"excerpts": "...representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.",
"relevance": 0.8,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/abbv-20260706.htm",
"filing_date": "2026-07-06",
"filing_year": 2026,
"fiscal_year_end": "07/06",
"sales_relevance": "Efficiency tools needed",
"signal_category": "financial"
}
}
curl https://signals.autobound.ai/v1/signals/54131994-c3c2-4e71-9101-434e802cb548 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.